share_log

港股异动 | CRO概念股早盘回暖 多家CRO企业发布澄清公告 政府工作报告首提“创新药”

Changes in Hong Kong stocks | CRO concept stocks pick up in early trading, many CRO companies issued clarifying announcements, government work reports first mention “innovative drugs”

Zhitong Finance ·  Mar 7 20:47

The Zhitong Finance App learned that CRO concept stocks picked up in early trading. As of press release, Viva Biotech (01873) rose 5.05% to HK$0.52; Pharmaceutical Kangde (02359) rose 4.11% to HK$46.85; Tiger Pharmaceuticals (03347) rose 3.66% to HK$25.5; Kanglong Chemical (03759) rose 3.89% to HK$46.75; Pharmaceutical Biotech (02269) rose 3.16% to HK$17.62.

According to the news, on March 6, the US Senate Homeland Security Committee held a hearing on the proposal. The US Senate version of the “Biosafety Act” (S3558) was passed with overwhelming approval votes at the meeting. Yao Ming Kangde and Yao Ming Biotech have both issued announcements, once again denying that the company poses a risk to the national security of the United States or other countries and will continue to monitor progress. Pharmaceutical Federation stated that the business will continue to operate normally.

Furthermore, the government work report stated in the “Actively Cultivating Emerging Industries and Future Industries” section: consolidate and expand leading advantages in industries such as intelligent connected new energy vehicles, accelerate the development of cutting-edge industries such as hydrogen energy, new materials, and innovative pharmaceuticals, and actively build new growth engines such as biomantry, commercial aerospace, and the low-altitude economy. It is worth noting that this is the term “innovative drug”. It is the first time it has entered the government work report, and it may push more local pharmaceutical companies to invest more and innovate.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment